<DOC>
	<DOCNO>NCT00810979</DOCNO>
	<brief_summary>The purpose study determine whether SLx-4090 combination statin therapy reduce LDL-C patient hyperlipidemia effectively statin therapy alone .</brief_summary>
	<brief_title>Comparison SLx-4090 Combined With Statin Therapy Versus Statin Alone Reducing LDL-C Patients With Hyperlipidemia</brief_title>
	<detailed_description>1 . LDL-C 12 week treatment 2 . Safety tolerability 3 . Plasma level SLx-4090</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>LDLC &gt; = 100 mg/dL On stable statin therapy least 6 week Coronary heart disease risk factor CHD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>